
Around 1 in 5 people diagnosed with cancer in the UK take part in a clinical trial.
Please note - this trial is no longer recruiting patients. We hope to add results when they are available.
Researchers are looking for new ways to help people with solid tumours that have spread or continued to grow despite treatments. In this trial they are looking at a new drug called guadecitabine.
Guadecitabine is a type of drug called a demethylating agent. It helps the immune system to spot the cancer, which helps pembrolizumab to work better.
Guadecitabine is similar to a drug called decitabine. Decitabine is already a possible treatment for people with acute myeloid leukaemia (AML). Doctors think that guadecitabine might work better than decitabine, but they need to find out for sure.
Pembrolizumab (Keytruda) is a targeted drug called a monoclonal antibody. It stimulates the immune system to fight cancer cells. Pembrolizumab is already a possible treatment for people with non small cell lung cancer (NSCLC) and melanoma.
This trial is in 2 parts. In the first part, researchers wanted to find the best dose of guadecitabine that you can safely have with pembrolizumab. This part is now closed. Researchers are now looking for people to join part 2.
In the second part of this trial, everyone has the best dose of guadecitabine and pembrolizumab found during part 1. Doctors want to find out how well pembrolizumab and guadecitabine work and the effect it has on the body.
Guadecitabine is a new drug, so there might be side effects we don’t know about yet.
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Professor Johann de Bono
Astex Pharmaceuticals
Institute of Cancer Research (ICR)
MSD
The Royal Marsden NHS Foundation Trust
Freephone 0808 800 4040
Around 1 in 5 people diagnosed with cancer in the UK take part in a clinical trial.